Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2024 Earnings Call Transcript

Sean Dodge: Okay. So Q1 then does not kind of fully reflect what will be like a full load of the gene therapy cost. There should be a step-up in as we think about…

Dan Hart: There will be, Sean but that will be over time. That’s not going to be, say, in the next quarter. It will be as the bookings and the revenues increase on that side.

Operator: Thank you. And I’m showing no further questions. I would now like to turn the call back over to Nick Green for closing remarks.

Nick Green: Thank you, operator and thank you to everyone participating on today’s call. In closing, as we mark Avid’s 30th year in business, we’d like to acknowledge the substantial progress we’ve made in recent years. We thank our customers for their trust and partnership and our investors for their continued support and we wish also to recognize the exceptional employees who continue to drive this success. Thank you for participating today in today’s call and for your continued support of Avid Bioservices. Thank you.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.